MaxCyte applies for Nasdaq dual listing, public offering

MaxCyte Inc., a Gaithersburg provider of platform technologies for cell engineering, announced Friday it has submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market. The number of securities to be offered and the ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.